About this medicine
Product information is provided to support understanding and conversations with your care team. Follow the approved leaflet and your prescriber’s instructions.
Content migrated from the company website; pending clinical review before final publication.
Dosage forms
Oral capsules (75, 100 and 125 mg)
Drug class
Cell-cycle inhibitor; CDK4/6 (cyclin-dependent kinase) inhibitor
Administration
Usually taken as 125 mg daily in four-week treatment cycles (three weeks of treatment followed by one week off). Take with food.
Uses
• Advanced or metastatic HR-positive, HER2-negative breast cancer
Competitive advantages
By inhibiting CDK4 and CDK6, which have an important role in cancer-cell proliferation, palbociclib effectively controls the growth and proliferation of breast cancer cells. It has shown particular effectiveness in patients with HR-positive, HER2-negative breast cancer who have not responded to previous treatments.
Combining palbociclib with hormone therapy provides greater effectiveness in controlling disease and substantially increases patients’ progression-free survival (PFS). Its acceptable safety profile and ability to improve disease control make it a desirable choice for patients with advanced breast cancer.
Original company product page ↗